As newer classes of targeted therapies are developed, such as KRAS, P53, PI3K and EGFR inhibitors53, and more anti-lung cancer drugs are developed to specific genetic targets, it is important to develop immunocompetent mouse models capable of responding to treatments. The gene discussed is TP53; the disease is lung carcinoma.